You are here:
16 November 2018 / news

Life Sciences Bit: The Netherlands and Flanders join forces in personalised medicine

On 5 November 2018, the Dutch Ministry of Economic Affairs and Climate and the Flanders Department of Economics, Science and Innovation entered into a memorandum of understanding (MoU) on personalised medicine.

Are you ready for the medicines verification system?

Download

The parties to the memorandum refer to the definition of personalised medicine used by the Council of the EU (2015/C 421/03): “There is no commonly agreed definition of the term ‘personalised medicine’. However, it is widely understood that personalised medicine refers to a medical model using characterisation of individuals’ phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention. Personalised medicine relates to the broader concept of patient-centred care, which takes into account that, in general, healthcare systems need to better respond to patient needs.

The parties to the MoU have agreed to cooperate on research, development, innovation and entrepreneurship in the field of personalized medicine for a period of five years. In that regard, they have defined three new focus areas: cell-based technologies, prevention (life style health) and personal data infrastructure and management (including state of the art technology such as FAIR principles and Personal Health train). The fourth focus area is regenerative medicine, on which the parties have been cooperating since two years already.

One of the key points in the MoU is that the parties aim to involve a wide spectrum of public and private parties. Private co-funding and involvement is a prerequisite for setting and implementing the final agenda.

A detailed research agenda will be published in spring 2019.

The Loyens & Loeff Life Sciences Team consists among others of both Belgian and Dutch members, which makes us the perfect partner if you are interested to know more about the Dutch-Belgian cooperation in the field of personalised medicine.

Should you have any questions regarding the above, please do not hesitate to contact Joost Dibbits or your regular Loyens & Loeff advisor.

Follow our Showcase Page on LinkedIn for updates and more Life Sciences Bits.